AB117-1mg / 询价
- 关联产品
- 客服电话
- 技术支持
Anti-CD30 Antibody (Brentuximab Biosimilar)
Human/Cynomolgus
CD30
Human IgG1-Kappa
Unconjugated
protein A
0.2 μM filtered
PBS, 10% glycerol (pH 7.4)
Less than 1 EU per μg by the LAL method.
（Recommended Dilution Buffer）
PBS (pH 7.4), contains no stabilizers or preservatives.
<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>
<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>
ELISA
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
